Ripple Therapeutics Corporation

Ian Charles Parrag

Matthew Alexander John Statham

Kyle Giovanni Battiston

Wendy Alison Naimark

Hans Christian Fischer

Dimitra Louka

Paul Joseph Santerre

Georgios Rizis

Leonard Pinchuk

Boris Gorin

Roseita Esfand

Bahareh Khalili

Judith Anne Williams

Elizabeth Poloz

Jared A Demorat

Robert William Henson

Eli B Nichols

Emma-Louise Elizabeth Moore

Provided herein are (e.g., controlled release) compositions for the treatment of acute or chronic diseases or disorders. Described herein are processable opioid conjugates. Also described herein are compositions and methods for the treatment of central nervous system (CNS) diseases or disorders including chronic pain (e.g., cancer pain), acute pain, opioid addiction, alcohol addiction, alcohol dependence, opioid-induced constipation, and narcotic depression. Said compositions and methods comprise opioid agonists and/or opioid antagonists, which demonstrate CNS activity and/or other desirable activities. Injection of said compositions subcutaneously or intraspinally provides therapeutic benefit to individuals suffering from CNS diseases or disorders.

Compositions and methods for the treatment of pain and dependence disorders

The disclosure features polymorphs of a prodrug dimer of dexamethasone linked at the 21-C and 21'-C carbons via a carbonate-triethylene glycol-carbonate linker. Also disclosed are pharmaceutical compositions and articles comprising said polymorphs, and the use thereof in the treatment of a disease or condition, e.g. via the extended or controlled release of dexamethasone from said articles.

Crystalline forms of dexamethasone dimers and uses thereof

The disclosure relates to compounds and compositions for sustained release of ocular therapeutics.

Ocular inserts comprising a covalently linked steroid dimer

Provided herein are needle assemblies for intravitreal injection of an implant into an eye of a patient through an unsheathed state and a sheathed state. Such needle assemblies are precise and accurate for proper treatment and prevent further damage to the eye.

Intravitreal injector

Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

Heterodimer compositions and methods for the treatment of ocular disorders

The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

Dexamethasone prodrug compositions and uses thereof

The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

Growing community of inventors

Mississauga, Canada

Ian Charles Parrag